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Judy Lieberman
Boston Children’s Hospital
A decade after RNAi was found in mam-
mals, clinical studies using microRNA
antagonists and lipid-encapsulated
siRNAs are showing promise for inhibiting
hepatitis C virus replication and knocking
down genes in the liver. The biggest chal-
lenge to RNA-based cancer therapeutics
remains delivery into cells outside of the
liver, which is critical for treating dissemi-
nated cancer. Attractive approaches to
targeted delivery being developed avoid
liposomes and use RNAs covalently linked
to small-molecule conjugates or RNA
aptamers. siRNA cocktails can sidestep
the dangers of cancer escape mutations,
since multiple mutations generally com-
promise fitness. The choice of siRNA
targets may need to be customized based
on each tumor’s unique dependencies;
siRNA drugs are ideally suited to personal-
ized therapy. siRNA cocktails could be
selected, based on a tumor’s molecular
fingerprint, from a siRNA pharmacy of the
future containing hundreds of RNAs. In
addition, mimics of tumor suppressor mi-
croRNAs (which have the same delivery
issues as siRNAs) could provide a way to
manipulate large networks of genes to
inhibit tumor proliferation or metastasis or
induce differentiation. It will be difficult for
tumors to escape from these broadly
acting RNAs. It is becoming clear that
long noncoding RNAs regulate transcrip-
tion, maintain heterochromatin, promote
enhancer function, and help to repair DNA
damage—all processes central to malig-
nant transformation and cancer treatment.
RNA-based drugs that manipulate these
newer noncoding RNA functions provide
a therapeutic opportunity worth exploring.The Promise of Small RNAs
Frank Slack
Yale University
From the initial reports of microRNAs and
RNAi in C. elegans, it is now clear that
small RNAs play big regulatory roles in
almost all species and regulated pro-
cesses. Given their roles in regulating
key human disease genes, they now
show promise as therapeutics for a whole
range of human ills. Our understanding of
microRNAs in cancer is best developed,
and even though the first human micro-
RNA was only discovered in 2000, the
field has already moved past the dis-
covery stage into the translational phase.
Because certain microRNAs are overex-
pressed in cancer and have oncogenic
properties (oncomiRs), whereas others
are lost in cancer and have tumor sup-
pressor (TS) properties, the field has
a two-pronged strategy: inhibit the onco-
miRs (therapeutic target strategy) and
restore the TS microRNAs (targeted ther-
apeutic strategy). Both strategies show
promise alone in mouse models of
cancer, but it is likely that a combination
of the two will be required for efficacy in
the heterogeneous background of human
cancer. This nascent field has benefited
immensely from the prior knowledge and
chemical innovations developed for oligo
and siRNA therapeutics, and it suffers
from some of the same drawbacks and
challenges. Enhancing effective delivery
and stability while eliminating potential
side effects are perennial issues being
addressed with novel nanoparticle strate-
gies. The ingenuity of nanoengineering is
highly likely to make this promise a reality
for patients.CellGenomic Dark Matter
Pier Paolo Pandolfi
Beth Israel Deaconess Medical Center, Harvard
University
I believe that cancer research, diagnosis,
andcarewill be revolutionizedby the impact
of thenoncodingRNAdimension.However,
despite intensive research, the functions of
the noncoding portion of the genome have
largely remained uncharted territory. We
discovered that pseudogenes, noncoding
RNA species, and, importantly, protein-
codingmRNAs can function as competitive
endogenous RNAs (ceRNAs) and compete
for a limited pool ofmicroRNAs. Such com-
petition leads to crosstalk that can be pre-
dicted based on number and identity of
shared microRNA response elements
(MREs), the letters of the ‘‘MRE language,’’
andallows the formationof complex regula-
tory networks. Such networks are crucial in
lending robustness to evolutionarily con-
served biological systems while permitting
speciation and diversification but also pro-
mote disease when their balance is per-
turbed. The identification of the ceRNA
dimension will allow us to unravel and func-
tionalize large portions of the ‘‘dark matter’’
of the genome. Once such knowledge has
been integrated with our model of the
protein-coding world, we will be one step
closer to understanding the biology of
cells. We are currently approaching this by
interrogating one noncoding RNA at a time
in cells and animal models. I believe, how-
ever, that bringing together systems biolo-
gists, mouse modelers, bioinformaticians,
and molecular biologists will more rapidly
identify the critical nodes in these complex
networks and their contribution to disease.
This, in turn, will provide novel potential
drug candidates that can be explored for




Emerging evidence suggests that the
vast, often uncharted, noncoding land-
scape of the human genome plays an
important role in biology and disease
progression. Small ncRNAs, such as
microRNAs, have well-established differ-
ential patterns of expression in cancer
and function as tumor suppressors or
oncogenes by silencing target gene
expression. Much less is known about
their longer cousins, long noncoding
RNAs (lncRNAs), subsets of which have
been characterized as epigenetic factors,
enhancers, antisense transcripts, and
pseudogenes. The popularization of RNA-
seq technology to interrogate the tran-
scriptome has revealed the pervasive
expression of lncRNAs in cancer progres-
sion. While the research community is
still in the early days of characterizing
lncRNAs across tumor types, lineage-
specific and sometimes cancer-specific
patterns of expression are emerging.
The function of most lncRNAs in cancer
remains a mystery. Prototypical lncRNAs
have been shown to be overexpressed
in subsets of cancers, interact with epige-
netic complexes, be recruited to DNA
sequences as enhancers, and function in
RNA-RNA hybrids. A major challenge in
understanding the function of a specific
lncRNA in cancer is deciphering its ‘‘inter-
actome’’—whether it be with specific
protein complexes, regions of DNA, or
other RNAs. Several high-throughput
technologies are now emerging to
address this gap. Ultimately, lncRNAs
will likely have implications in cancer
management, including the development
of more specific cancer biomarkers, due
to their lineage- and cancer-specific
properties.10 Cell 153, March 28, 2013 ª2013 Elsevier IAssessing RNA Therapies
Reuven Agami
The Netherlands Cancer Institute
The past decade has witnessed a swift
advance in the identification of micro-
RNAs with disease-specific expression
patterns and those with causative roles
in disease development and—in the
case of cancer—in resistance to therapy.
This has led to the initiation of clinical
trials testing oligonucleotide-based thera-
pies inhibiting or mimicking microRNAs.
With their simple design, scalability, and
systemic delivery to the body, oligonucle-
otide-based therapy is easier to develop,
improve, and put to practice than gene-
and drug-based therapies. The outcome
of these trials will determine how valuable
microRNAs are as therapeutic targets.
Concerning cancer, I thus believe that
the greatest challenge ahead is to
convincingly demonstrate efficient oligo-
nucleotide delivery accompanied by
long-lasting effects on tumor cells in
patients. Particularly, specificity and
safety of treatment should be demon-
strated, as some microRNAs can function
as both oncogenes and tumor suppres-
sors, depending on the targeted tissue.
In contrast to microRNAs, the research
field of lncRNA lags far behind. Their
recent identification, long size, low ex-
pression level, and excessive structure
delay progress. Although they are as
powerful as microRNAs in controlling
essential cellular processes, dedicated
preclinical investigation of lncRNAs is
required to decode the language that
they talk and the words they use in order
to discover the best ways to control their
function. Only when such a pronounced
fundamental understanding is achieved
can we start implementing lncRNAs in
therapy.nc.Revealing ncRNA Disease Roles
Joshua T. Mendell
UT Southwestern Medical Center
Over the last decade, numerous studies
havedocumented thepotent pro- andanti-
tumorigenic functions of noncoding RNAs
(ncRNAs) and, particularly, microRNAs
(miRNAs). Understanding how aberrant
ncRNAactivitymechanistically contributes
to tumorigenesis and predicting the
sequelae of targeting ncRNAs therapeuti-
cally require a deeper understanding of
the roles of ncRNAs in normal physiology
in vivo. Functional studies of miRNAs and
other ncRNAs in knockout and transgenic
mice have repeatedly revealed surprisingly
subtle phenotypes that can be enhanced
by various forms of stress, including acute
injury and chronic disease. Based on this
emerging paradigm, animals with ncRNA
knockout or overexpression should be
exposed to broad panels of perturbations
to reveal defective pathways that might
not be apparent in controlled laboratory
environments. Mechanistically dissecting
these phenotypes in whole animals poses
a daunting challenge. It is often stated
that miRNAs fine-tune the expression of
many messenger RNAs simultaneously.
Likewise, long ncRNAs are often compo-
nents of broadly acting chromatin-modi-
fying complexes. Subtle regulation of a
large number of targets may, in aggregate,
result in profound effects on cellular
behavior. Yet it remains possible that
many ncRNA-driven phenotypes result
from the regulation of a few key targets
hidden within these extensive networks.
Uncovering these critical nodes, should
they exist, will be essential for under-
standing ncRNA functions in physiology
and pathophysiology. Moreover, these
crucial effectors of ncRNA activity may
themselves represent druggable targets,
potentially offering greater specificity and
easeof targeting thanncRNAs themselves.
